FIGURE 3:

(A) Renal protein expression (n = 4–5 per group, two representative bands per animal shown) and average quantification per group (bar graphs) for tumor necrosis factor alpha (TNF-α), nuclear factor kappa (NFκ)-B, monocyte-chemoattractant protein (MCP)-1, interleukin 6 (IL-6), IL-10, and IL-12 in normal, RVD and RVD + macitentan kidneys. (B) (Top) Representative histological slides of stenotic kidneys of RVD and RVD + macitentan showing positive staining for F4/80⁺ cells at both ×20 and ×40 magnification (right, top and bottom rows, respectively) and average histological counts (left) of F4/80⁺ cells. (Bottom) Representative pictures (×20) showing immunoreactivity against IL-6, IL-10 and IL-12 from stenotic kidneys, untreated and treated with macitentan. Treatment with macitentan for 4 weeks attenuated inflammation in the stenotic kidney (*P < 0.05 versus normal, ^†P < 0.05 versus RVD, ^{^}P=0.07 versus normal).